Cerebrolysin: Multi-Peptide Neurotrophic Complex
Cerebrolysin is a pharmaceutical mixture of neuropeptides and amino acids derived from porcine brain tissue, studied for neuroprotection, stroke recovery, traumatic brain injury, and cognitive decline.
🧬 Neuroprotection
Shown to reduce neuronal death and promote survival in ischemic and degenerative models.
⚡ Cognitive Enhancement
RCTs indicate improvements in cognition, attention, and daily function in dementia patients.
🏥 Stroke Recovery
Used acutely in many countries to support neurological recovery post-stroke.
What Is Cerebrolysin?
Cerebrolysin is a standardized injectable blend of low-molecular-weight neuropeptides designed to mimic the effects of endogenous neurotrophic factors. It has decades of use and research in Europe and Asia.
- Supports neuroplasticity and synaptic repair
- Reduces excitotoxicity and oxidative stress
- Promotes neuronal survival pathways
Evidence & Clinical Applications
Cerebrolysin has been studied in:
- Ischemic stroke – improved functional recovery when used early
- Alzheimer’s disease & dementia – modest cognitive improvements in several RCTs
- TBI (Traumatic Brain Injury) – neuroprotective and functional benefits in some studies
Regulatory Status
- Approved in **over 40 countries** (not the U.S.) for neurologic indications.
- Requires **prescription** and **medical supervision**.
- Quality-controlled pharmaceutical product — not a research peptide.
Administration (Educational Overview)
- Typically IV or IM injections
- Course lengths 10–20 days in clinical protocols
- Often cycled several times per year
Safety & Considerations
- Generally well tolerated in clinical trials
- Possible side effects: headache, dizziness, restlessness
- Not appropriate for seizures without supervision
Plain-Language Summary
Cerebrolysin is one of the most clinically studied neuropeptide therapies in the world, with evidence supporting its role in neuroprotection and recovery from neurological injury — though access varies by region.